ACP 2025: Laura Davisson, MD, outlines how PCPs can navigate GLP-1 medication coverage issues and why to consider recent cash-pay options.
In this interview from the ACP Internal Medicine Meeting 2025, Laura Davisson, MD, professor of medicine, West Virginia University School of Medicine, discusses the rapidly evolving landscape of GLP-1 receptor agonist access, including challenges related to insurance coverage and medication shortages. With expanding FDA indications for medications like Wegovy and Zepbound, and recent manufacturer announcements introducing more affordable cash-pay options, primary care physicians need up-to-date knowledge to guide patient access. The conversation offers practical strategies for navigating insurance barriers, exploring new diagnosis-based indications, and considering cash-pay alternatives as these popular therapies become more accessible.
2 Commerce Drive
Cranbury, NJ 08512